These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18473975)

  • 1. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
    Büchele T
    Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 antisense therapy in multiple myeloma.
    Chanan-Khan AA
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):21-4. PubMed ID: 15651173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.
    Advani PP; Paulus A; Masood A; Sher T; Chanan-Khan A
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):765-74. PubMed ID: 21521129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM; Cunningham CC; Golenkov AK; Turkina AG; Novick SC; Rai KR
    J Clin Oncol; 2005 Oct; 23(30):7697-702. PubMed ID: 16186597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA; Kirkwood JM
    Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 antisense therapy in hematologic malignancies.
    Chanan-Khan A
    Curr Opin Oncol; 2004 Nov; 16(6):581-5. PubMed ID: 15627020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A
    Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
    J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
    J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genasense (Genta Inc).
    Banerjee D
    Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.